Mutual of America Capital Management LLC Buys 55 Shares of Axon Enterprise, Inc $AXON

Mutual of America Capital Management LLC raised its stake in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 0.5% during the 2nd quarter, according to its most recent filing with the SEC. The firm owned 10,144 shares of the biotechnology company’s stock after acquiring an additional 55 shares during the period. Mutual of America Capital Management LLC’s holdings in Axon Enterprise were worth $8,399,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of AXON. Vanguard Group Inc. lifted its stake in shares of Axon Enterprise by 2.2% in the 1st quarter. Vanguard Group Inc. now owns 8,632,008 shares of the biotechnology company’s stock worth $4,540,005,000 after purchasing an additional 185,571 shares during the period. Alliancebernstein L.P. lifted its stake in shares of Axon Enterprise by 15.9% in the 1st quarter. Alliancebernstein L.P. now owns 1,284,935 shares of the biotechnology company’s stock worth $675,812,000 after purchasing an additional 175,890 shares during the period. Westfield Capital Management Co. LP lifted its stake in shares of Axon Enterprise by 29.8% in the 1st quarter. Westfield Capital Management Co. LP now owns 927,801 shares of the biotechnology company’s stock worth $487,977,000 after purchasing an additional 212,931 shares during the period. Northern Trust Corp lifted its stake in shares of Axon Enterprise by 1.2% in the 1st quarter. Northern Trust Corp now owns 725,720 shares of the biotechnology company’s stock worth $381,692,000 after purchasing an additional 8,794 shares during the period. Finally, Jennison Associates LLC lifted its stake in shares of Axon Enterprise by 23,203.7% in the 1st quarter. Jennison Associates LLC now owns 614,053 shares of the biotechnology company’s stock worth $322,961,000 after purchasing an additional 611,418 shares during the period. Institutional investors own 79.08% of the company’s stock.

Insider Buying and Selling at Axon Enterprise

In other Axon Enterprise news, CEO Patrick W. Smith sold 10,000 shares of the stock in a transaction that occurred on Tuesday, October 7th. The shares were sold at an average price of $713.74, for a total transaction of $7,137,400.00. Following the completion of the sale, the chief executive officer directly owned 3,033,982 shares of the company’s stock, valued at $2,165,474,312.68. This trade represents a 0.33% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Brittany Bagley sold 5,000 shares of the stock in a transaction that occurred on Monday, September 29th. The shares were sold at an average price of $713.88, for a total transaction of $3,569,400.00. Following the sale, the chief financial officer directly owned 93,592 shares of the company’s stock, valued at approximately $66,813,456.96. This trade represents a 5.07% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 59,932 shares of company stock worth $45,115,616. Insiders own 5.70% of the company’s stock.

Axon Enterprise Price Performance

NASDAQ AXON opened at $683.13 on Tuesday. Axon Enterprise, Inc has a 12 month low of $422.38 and a 12 month high of $885.91. The stock has a market cap of $53.63 billion, a price-to-earnings ratio of 168.67, a PEG ratio of 26.04 and a beta of 1.41. The company’s 50 day moving average is $736.73 and its two-hundred day moving average is $720.91. The company has a current ratio of 2.95, a quick ratio of 2.71 and a debt-to-equity ratio of 0.63.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings data on Monday, August 4th. The biotechnology company reported $2.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.54 by $0.58. Axon Enterprise had a net margin of 13.64% and a return on equity of 6.80%. The business had revenue of $668.54 million during the quarter, compared to analyst estimates of $641.77 million. During the same period last year, the firm posted $1.20 EPS. The company’s revenue was up 32.6% on a year-over-year basis. Axon Enterprise has set its FY 2025 guidance at EPS. As a group, research analysts anticipate that Axon Enterprise, Inc will post 5.8 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. Bank of America increased their price objective on shares of Axon Enterprise from $895.00 to $1,000.00 and gave the stock a “buy” rating in a research note on Wednesday, August 6th. Raymond James Financial reiterated an “outperform” rating and issued a $855.00 price objective (up previously from $645.00) on shares of Axon Enterprise in a research note on Tuesday, August 5th. Wolfe Research began coverage on shares of Axon Enterprise in a research note on Monday, July 7th. They set an “outperform” rating on the stock. UBS Group restated a “neutral” rating and set a $840.00 target price (up previously from $820.00) on shares of Axon Enterprise in a research note on Tuesday, August 5th. Finally, Morgan Stanley set a $885.00 target price on shares of Axon Enterprise and gave the stock an “overweight” rating in a research note on Friday, July 11th. Fourteen analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $841.64.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.